Skip to main content

Table 2 Patient characteristics and the association with ACVR1B gene status

From: Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer

Patients characteristics ACVR1B gene P
  Not deletion (n = 23) Deletion (n = 6)  
Age    
<70 years 15 3 0.65
≥ 70 years 8 3
Gender    
Male 12 3 1.00
Female 11 3
Primary size    
<2 cm 18 5 1.00
≥2 cm 5 1
Lymph node metastasis    
Negative 4 0 0.55
Positive 19 6
Distant metastasis    
Negative 10 4 0.39
Positive 13 2
SMAD4 gene status    
Not deletion 18 1 0.011*
Deletion 5 5
Treatment    
Best supportive care 4 2 0.59
Chemotherapy 17 4
Unknown 2 0  
Response to chemotherapy    
PR 7 1 1.00
SD or PD 10 3
Median PFS (days) 252 167 0.89
Median OS (days) 344 215 0.66
  1. ACVR1B, activin receptor A, type IB; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival. PFS and OS were analyzed by log-rank test and the others by Fisher exact test.
  2. Legend: Six patients (6/29, 20.7%) had a deletion of ACVR1B gene, 10 patients (10/29, 34.5%) had a deletion of SMAD4 gene. Five of the 6 patients with a deletion of the ACVR1B gene also had a deletion of the SMAD4 gene (P = 0.011), but no significant differences in the other patient characteristics were observed between the two groups. Among 21 patients who received chemotherapy, no significant differences in PFS or OS were seen between the two groups.